Pfizer lines up a potential $687M rare disease buyout to expand its stake in the hot gene therapy field
In the latest sign that the major biopharma players are eagerly joining the big tech rush on the gene therapy market, Pfizer has snagged an option to buy a Paris-based biotech with a lead program a rare liver disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
